Opinion|Videos|February 4, 2025
Navigating BCG-Unresponsive NMIBC and Emerging Therapies
Author(s)Mark D. Tyson, II, MD, MPH
A panelist discusses how BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) has evolved from having limited treatment options beyond radical cystectomy to now having several therapeutic alternatives including intravesical chemotherapy and immunotherapy, though each current option comes with its own efficacy limitations and adverse effect profiles that must be carefully weighed against patient factors.
Advertisement
Episodes in this series
- Would you please start by giving a brief overview of BCG-unresponsive NMIBC?
- Prior to recent therapeutic innovations in the bladder space, what challenges or unmet needs did you face when treating these patients?
- Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.
- What advantages and limitations do these options have?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Alternative BCG strains may help address ongoing supply challenges in NMIBC
2
Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
5